Biogen Collaborator Alcyone Therapeutics Announced First Patient Implanted In PIERRE Study, Its Collaboration With Biogen, To Evaluate Safety And Performance Of ThecaFlex DRx System For Administration Of SPINRAZA
Portfolio Pulse from Benzinga Newsdesk
Alcyone Therapeutics has announced the first patient implantation in the PIERRE study, a collaboration with Biogen, to evaluate the safety and performance of the ThecaFlex DRx System for the administration of SPINRAZA. The ThecaFlex DRx System, an FDA Breakthrough designated device, is designed to facilitate subcutaneous delivery of therapeutics to the cerebrospinal fluid. The procedure was performed at Texas Children's Hospital by Dr. David Bauer.
January 03, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen, in collaboration with Alcyone Therapeutics, has reached a milestone with the first patient implantation of the ThecaFlex DRx System for SPINRAZA administration in the PIERRE study.
The news of the first patient implantation is a positive development for Biogen, indicating progress in the PIERRE study. The collaboration with Alcyone and the potential for improved patient experience with the ThecaFlex DRx System could be seen favorably by investors and may have a positive short-term impact on Biogen's stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80